HLA-DRB1 and myeloid sarcoma: In support of this study, Michaela et al. examined the association between 52 risk variants identified through genome-wide association studies (GWASs) and disease severity in MS and found that they were not associated with MS severity in terms of cohort, gender, age of onset, and HLA-DRB1*15:01 allele [21].